MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FERTEL, R.
Right arrow Articles by WEISS, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FERTEL, R.
Right arrow Articles by WEISS, B.

Molecular Pharmacology, Vol 12, 678-687, Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics

Properties and Drug Responsiveness of Cyclic Nucleotide Phosphodiesterases of Rat Lung

RICHARD FERTEL 1 and BENJAMIN WEISS 1

1 Department of Pharmacology, Medical College of Pennsylvania, Philadelphia, Pennsylvania 19129

Cyclic 3',5'-AMP phosphodiesterase and cyclic 3',5'-GMP phosphodiesterase of rat lung were found predominantly in the 100,000 x g supernatant fraction. Both enzymes had biphasic Hofstee plots, with apparent Km values of 0.3 µM and 115 µM for cyclic AMP, and 1.5 µM and 19 µM for cyclic GMP. Electrophoretic analysis of the soluble supernatant fraction of lung on a preparative polyacrylamide gel column showed two stable peaks of phosphodiesterase activity. The first peak, which had relatively little phosphodiesterase activity, hydrolyzed only cyclic AMP, whereas the other peak hydrolyzed both cyclic AMP and cyclic GMP. Both peaks of cyclic AMP phosphodiesterase activity of lung had biphasic Hofstee plots. The first had apparent Km values of 2.9 µM and 200 µM, and the second had Km values of 1.9 µM and 190 µM; the cyclic GMP peak had a single Km of 7 µM. These peaks of phosphodiesterase were markedly different in their response to drugs; the first peak was highly resistant to pharmacological inhibition while the second was sensitive to several phosphodiesterase inhibitors. For example, the inhibitor constant (Ki) of trifluoperazine was approximately 1000 µM for the first peak but only about 50 µM for the second peak. In this second peak, both cyclic AMP and cyclic GMP phosphodiesterase activities were inhibited to a similar extent by a variety of inhibitors. Neither the cyclic AMP nor cyclic GMP phosphodiesterase of crude or electrophoretically purified fractions was significantly activated by a heat-stable factor derived from rat cerebrum on rat lung. However, the lung does contain an activator of phosphodiesterase which is capable of stimulating brain phosphodiesterase. The differential effects of inhibitors on the multiple forms of phosphodiesterase suggest that the concentration of cyclic nucleotides in lung may be selectively altered by appropriate pharmacological agents.

Note:
ACKNOWLEDGMENT We acknowledge with thanks the expert technical assistance of Mr. Thomas Wallace.

Submitted on June 24, 1975







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1976 by the American Society for Pharmacology and Experimental Therapeutics